The hottest thing in cancer drug development is a takeover target again — here’s what you need to know about it – Business Insider
Business Insider |
The hottest thing in cancer drug development is a takeover target again — here's what you need to know about it
Business Insider Instead of getting a better, updated therapy for a disease every decade or so, we might begin to see second-generation cell therapies in a few years. One challenge these therapies still face is how toxic they can be. CAR–T's side effects can be deadly … CAR T-Cell Therapy Gets Priority Review for Lymphoma Treatment FDA Grants Priority Review to CAR T-Cell Therapy Tisagenlecleucel for DLBCL Speedy EU, US review for Novartis' CAR–T therapy Kymriah |
